OverviewSuggest Edit

Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. The Company has built a diverse portfolio of disease-modifying therapies, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide.

TypePublic
Founded1991
HQLeuven, BE
Websiteoxurion.com

Latest Updates

Employees (est.) (Dec 2018)78(+6%)
Share Price (Nov 2021)€2.2
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Oxurion

Adrienne Graves

Adrienne Graves

Non-Executive Director
David Guyer

David Guyer

Non-Executive Director
Emmanuèle Attout

Emmanuèle Attout

Non-Executive, Independent Director
Philippe Vlerick

Philippe Vlerick

Non-Executive, Independent Director
Grace Chang

Grace Chang

Chief Medical Officer
Kathleen Paisley

Kathleen Paisley

Chief Legal Officer and General Counsel
Show more

Oxurion Office Locations

Oxurion has offices in Leuven, Dublin 8 and Dublin
Leuven, BE (HQ)
1 Gaston Geenslaan
Dublin,
Office 109A 12 Camden Row
Dublin 8, IE
109A, 12 Camden Row, Saint Kevin's, Dublin
Show all (3)

Oxurion Financials and Metrics

Oxurion Revenue

Market capitalization (10-Nov-2021)

84.1m

Closing stock price (10-Nov-2021)

2.2
Oxurion's current market capitalization is €84.1 m.
Show all financial metrics

Oxurion Cybersecurity Score

Cybersecurity ratingPremium dataset

B

80/100

SecurityScorecard logo

Oxurion Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Oxurion Online and Social Media Presence

Embed Graph

Oxurion News and Updates

Oxurion NV Announces Initiation of Equity Analyst Coverage by H.C. Wainwright with a “Buy” Recommendation

Leuven, BE, Boston, MA, US – November 4, 2021 – 07.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, announces that H.C. Wainwright has initiat…

Oxurion NV Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the treatment of Diabetic Macular Edema (DME)

Leuven, BE, Boston, MA, US – October 13, 2021 – 07.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, announces that the first patient has been …

Oxurion NV - Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science, the American Academy of Ophthalmology Journal

THR-687 is a potent pan-RGD integrin antagonist holding potential as next generation first line therapy for DME, wet AMD and RVO

Oxurion NV - Journal of Pharmacokinetics and Pharmacodynamics highlights desirable PK/PD profiles of THR-687 and THR-149

THR-149 and THR-687 show targeted activity in the eye following intravitreal injection with low systemic exposure

Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149

Timeline Guidance for Both Programs Confirmed

Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group

Leuven, BE, Boston, MA, US – April 6, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care back of the eye therapies, today announces that is has agreed to a capital commitment of up to €30 Million with Negma Group.
Show more

Oxurion Blogs

Annual Report – Financial Information 2018

Annual Report – Financial Information 2018 Document:  Annual Report - financial information 2018.pdf Date:  Thursday, April 4, 2019

Company presentation

Company presentation Document:  OXURION_Corp presentation_012019.pdf Date:  Wednesday, January 9, 2019

Perspectives magazine 2018

Perspectives magazine 2018 Document:  032_Oxurion_Perspectives_Magazine.pdf Date:  Tuesday, September 18, 2018

Interim Financial Report - Half year results as of 30/06/2018

Interim Financial Report - Half year results as of 30/06/2018 Document:  TG GLOBAL - Financial report 30-06-2018 (EN) FINAL.pdf Date:  Friday, September 7, 2018

Oxurion Frequently Asked Questions

  • When was Oxurion founded?

    Oxurion was founded in 1991.

  • Who are Oxurion key executives?

    Oxurion's key executives are Adrienne Graves, David Guyer and Emmanuèle Attout.

  • How many employees does Oxurion have?

    Oxurion has 78 employees.

  • Who are Oxurion competitors?

    Competitors of Oxurion include Olainfarm, pixon and Celyad.

  • Where is Oxurion headquarters?

    Oxurion headquarters is located at 1 Gaston Geenslaan, Leuven.

  • Where are Oxurion offices?

    Oxurion has offices in Leuven, Dublin 8 and Dublin.

  • How many offices does Oxurion have?

    Oxurion has 3 offices.